- The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia
-
Lee J, Choi NK, Jung SY, Kim YJ, Seong JM, Oh SJ, Park BJ
- KMID: 797672
- J Prev Med Public Health.
- 2009 May;42(3):165-170.
- doi: 10.3961/jpmph.2009.42.3.165
OBJECTIVES: We evaluated the risk of fracture associated with hypotension-related adverse drug reaction caused by taking alpha blockers to treat benign prostatic hyperplasia (BPH). METHODS: We used the Health Insurance... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of Short Term Clinical Effects and Presumptive Mechanism of Botulinum Toxin Type A as a Treatment Modality of Benign Prostatic Hyperplasia
-
Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK
- KMID: 1381252
- Yonsei Med J.
- 2006 Oct;47(5):706-714.
- doi: 10.3349/ymj.2006.47.5.706
The purpose of this study was to evaluate the effect and investigate the putative mechanism of botulinum toxin type A (BTA) applied to the treatment of benign prostatic hyperplasia (BPH).... -
- CITED
-
- Close
- SHARE
-
- Close
- Impacts of the Quinazoline-Based Alpha1-Antagonist, Terazosin, and of the Sulfonamide Derivative, Tamsulosin, on Serum Prostate-Specific Antigen and Prostate Volume
-
Paick JS, Cho MC, Song SH, Kim SW, Ku JH
- KMID: 1786892
- J Korean Med Sci.
- 2008 Jun;23(3):509-513.
- doi: 10.3346/jkms.2008.23.3.509
The aim of this study was to compare the impacts of terazosin and tamsulosin, on prostate activity, i.e., serum prostate-specific antigen, total prostate volume (TPV), and transition zone volume (TZV).... -
- CITED
-
- Close
- SHARE
-
- Close
